pneumococcal 11-valent conjugate vaccine

The pneumococcal 11-valent conjugate vaccine (PCV11) is a biologic vaccine developed for the prevention of invasive pneumococcal disease and pneumonia caused by *Streptococcus pneumoniae*. This specific formulation consists of capsular polysaccharides from 11 pneumococcal serotypes (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F), each individually conjugated to either tetanus toxoid or diphtheria toxoid carrier proteins. By utilizing these carrier proteins, the vaccine induces a T-cell dependent immune response, which is critical for establishing protective immunity in infants and young children whose immune systems do not respond well to plain polysaccharide vaccines. In a significant randomized, double-blind, placebo-controlled Phase 3 trial conducted in the Philippines (the ARIVAC study), the vaccine demonstrated a 22.9% reduction in community-acquired radiologically confirmed pneumonia among children under two years of age. Although the trial proved the vaccine's efficacy and the significant role of pneumococcus in pediatric pneumonia, the developer, Sanofi, did not proceed with commercialization, and the vaccine was eventually superseded by other conjugate vaccines.

Other names

11-valent pneumococcal conjugate vaccine11PCVpneumococcal polysaccharide conjugate vaccine 11-valent